Search - tctmd.com

Displaying 581 - 600 of 786

Sort: Relevancy | Date

News Industry News

Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element™ Plus Platinum Chromium Stent System

June 04, 2012

News Daily News

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

L.A. McKeown

June 01, 2012

News Daily News

JAMA Letter: Damage to DES After Balloon Expansion Documented in All 4 FDA-Approved Devices

May 25, 2012

News Daily News

Stress Echo Appears Overused in Asymptomatic Patients after Revascularization

May 24, 2012

Presentation

Changes to Polymer Surface of Drug-Eluting Stents During Balloon Expansion

Presenter: 167498|Scott Denardo

May 24, 2012

News Daily News

Meta-analysis: Superior Efficacy with DES at No Cost to Safety

May 22, 2012

News Conference News EuroPCR 2012

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

Caitlin E. Cox

May 22, 2012

News Conference News EuroPCR 2012

No Clear Winner in Tests Between Biodegradable-Polymer DES vs. Conventional SES

Caitlin E. Cox

May 18, 2012

News Conference News EuroPCR 2012

Trials Take on Permanent- vs. Biodegradable-Polymer Technology

Caitlin E. Cox

May 17, 2012

News Conference News EuroPCR 2012

CIBELES: Xience Stands Up to Cypher for CTO PCI

Caitlin E. Cox

May 17, 2012

News Conference News EuroPCR 2012

Strong Showing for Bioabsorbable-Scaffold DES

Caitlin E. Cox

May 16, 2012

News Industry News

Medtronic IN.PACT Drug-Eluting Balloon Studies Show Significant Benefit of Novel Medical Device in Treating Narrowed Arteries

May 16, 2012

News Industry News

One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent

May 15, 2012

News Industry News

Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe

May 15, 2012

News Industry News

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

May 15, 2012

News Conference News

Study Examines Influence of Baseline Factors on Outcomes After CABG, PCI

L.A. McKeown

May 11, 2012

News Daily News

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

May 10, 2012

News Industry News

Clinical Data for OrbusNeich’s Combo Dual Therapy Stent™ Set for Presentation at EuroPCR 2012

May 08, 2012

News Daily News

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

L.A. McKeown

April 25, 2012

Presentation Fellows 2012

Next-Generation Technologies: Bioabsorbable Stents/Polymers, Drug-Eluting Balloons, and More

Presenter: Juan Granada

April 21, 2012

Advertisement

Boston Scientific Receives FDA Approval for 32 MM and 38 MM Lengths for PROMUS Element™ Plus Platinum Chromium Stent System

CREDO-Kyoto Published: Extended DAPT Appears to Raise Bleeding Without Curbing Ischemic Events

JAMA Letter: Damage to DES After Balloon Expansion Documented in All 4 FDA-Approved Devices

Stress Echo Appears Overused in Asymptomatic Patients after Revascularization

Changes to Polymer Surface of Drug-Eluting Stents During Balloon Expansion

Meta-analysis: Superior Efficacy with DES at No Cost to Safety

EuroPCR 2012: Biodegradable Devices, Imaging Take Center Stage

No Clear Winner in Tests Between Biodegradable-Polymer DES vs. Conventional SES

Trials Take on Permanent- vs. Biodegradable-Polymer Technology

CIBELES: Xience Stands Up to Cypher for CTO PCI

Strong Showing for Bioabsorbable-Scaffold DES

Medtronic IN.PACT Drug-Eluting Balloon Studies Show Significant Benefit of Novel Medical Device in Treating Narrowed Arteries

One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent

Medtronic Nets New Indications for Resolute Integrity Drug-Eluting Stent in Europe

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy

Study Examines Influence of Baseline Factors on Outcomes After CABG, PCI

Early Exercise Stress Testing After Primary PCI Simple, Safe, Economical

Clinical Data for OrbusNeich’s Combo Dual Therapy Stent™ Set for Presentation at EuroPCR 2012

Meta-Analysis: First-Gen DES Show Long-term Safety, Efficacy in STEMI Setting

Next-Generation Technologies: Bioabsorbable Stents/Polymers, Drug-Eluting Balloons, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content